N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide
• 英文别名: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide
• 化学式: C₁₅H₁₇N₃O₂
• 分子量: 271.319
• InChiKey: YMZFSPQBWIIQLA-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-硼-2-甲酸基呋喃 在 sodium hydroxide 、 甲酸 、 叔丁基锂 、 对甲苯磺酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 39.0h， 生成 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide
  参考文献：
  名称：

  Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia:  Synthesis and Structure−Activity Relationship

  摘要：

  N-[(3R)-1-Azabicyclo[2.2.2] oct-3-yl] furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha 7 neuronal nicotinic acetylcholine receptor (alpha 7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective alpha 7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.

  DOI：

  10.1021/jm0602413

文献信息

• Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
  申请人：——

  公开号：US20030045540A1

  公开（公告）日：2003-03-06

  The invention provides compounds of Formula I: 1 where in W is 2 These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中W为 这些化合物可以是药用盐或组合物的形式，也可以是消旋混合物或其纯对映体。Formula I的化合物可用于治疗已知涉及α7的疾病或症状。
• [EN] QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE<br/>[FR] MULTI-HETEROARYLES CYCLIQUES SUBSTITUES PAR QUINUCLIDINES POUR LE TRAITEMENT DE MALADIES
  申请人：UPJOHN CO

  公开号：WO2002100857A1

  公开（公告）日：2002-12-19

  The invention provides compounds of Formula (I), where in W is. These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.

  该发明提供了公式（I）的化合物，其中W是。这些化合物可以是药物盐或组合物，外消旋混合物或其纯对映体。公式（I）的化合物在制药学中用于治疗已知涉及α7的疾病或病症。
• Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds
  申请人：Corbett W. Jeffrey

  公开号：US20050245504A1

  公开（公告）日：2005-11-03

  The present invention relates to compositions and methods to treat diseases or condition with an α7 nAChR full agonist and an inhibitor of cholinesterase, and or beta secretase and or gamma secretase.

  本发明涉及利用α7 nAChR全激动剂和胆碱酯酶抑制剂，和/或beta秘鲁和/或gamma秘鲁的组合物和方法来治疗疾病或症状。
• Treatment of attention defecit hyperactivity disorder
  申请人：Rogers N. Bruce

  公开号：US20050107425A1

  公开（公告）日：2005-05-19

  The present invention relates to compositions and methods to treat ADHD with an α7 nAChR full agonist and psychostimulants and/or monoamine reuptake inhibitors.

  本发明涉及使用α7 nAChR全激动剂和精神刺激剂和/或单胺再摄取抑制剂的组合物和方法来治疗ADHD。
• Treatment of diseases with alpha-7nACh receptor full agonists
  申请人：Groppi E. Vincent

  公开号：US20060019984A1

  公开（公告）日：2006-01-26

  The present invention relates to compositions and methods to treat diseases or conditions with alpha-7 nicotinic acetylcholine receptor (AChR) full agonists by decreasing levels of tumor necrosis factor-alpha and/or by stimulating vascular angiogenesis.

  本发明涉及使用α-7烟碱乙酰胆碱受体（AChR）全激动剂治疗疾病或病症的组合物和方法，通过降低肿瘤坏死因子-α的水平和/或刺激血管生成来实现。